Investigational drug · Phase 3
YK-1169
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP).
Phase 3Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "YK-1169"
First trial start
2026
Jun 4, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YK-1169", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hospital-acquired Bacterial Pneumonia (HABP)
- Ventilator-associated Bacterial Pneumonia (VABP)
Approved drugs for the same conditions: Pneumonia · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "YK-1169" as an intervention, largest first.
- A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial PneumoniaPivotal-lookingNot yet recruiting
Nanjing Yoko Biomedical Co., Ltd.Industry
NCT07634198 · 590 participants (planned) · Start Jun 4, 2026 · Primary completion Apr 1, 2028
Drug: YK-1169; Ceftazidime-avibactam Injection · For: Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP)
Nanjing Yoko Biomedical Co., Ltd.Industry
NCT05588531 · 66 participants · Start Dec 20, 2021 · Primary completion Apr 2, 2022
Drug: Group 1:YK-1169; Group 2:YK-1169/Placebo Injection and 4 more · For: Pharmacokinetics
Sites: Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacokinetics of YK-1169 in healthy subjects and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation.
Li Y, Yan B, Guo S, et al. · Br J Clin Pharmacol 2023
Also in development for Hospital-acquired Bacterial Pneumonia (HABP)
- PralurbactamPhase 33 trials
Qilu Pharmaceutical Co., Ltd. · Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI)
- HRS-8427Phase 32 trials
Jiangsu HengRui Medicine Co., Ltd. · Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP), Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
- ASK0912Phase 21 trial
Jiangsu Aosaikang Pharmaceutical Co., Ltd. · Ventilator-associated Bacterial Pneumonia (VABP), Hospital-acquired Bacterial Pneumonia (HABP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.